Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 1/2014

01.01.2014

Advanced glycation end products: role in pathology of diabetic cardiomyopathy

verfasst von: Vijaya Lakshmi Bodiga, Sasidhar Reddy Eda, Sreedhar Bodiga

Erschienen in: Heart Failure Reviews | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Increasing evidence demonstrates that advanced glycation end products (AGEs) play a pivotal role in the development and progression of diabetic heart failure, although there are numerous other factors that mediate the disease response. AGEs are generated intra- and extracellularly as a result of chronic hyperglycemia. Then, following the interaction with receptors for advanced glycation end products (RAGEs), a series of events leading to vascular and myocardial damage are elicited and sustained, which include oxidative stress, increased inflammation, and enhanced extracellular matrix accumulation resulting in diastolic and systolic dysfunction. Whereas targeting glycemic control and treating additional risk factors, such as obesity, dyslipidemia, and hypertension, are mandatory to reduce chronic complications and prolong life expectancy in diabetic patients, drug therapy tailored to reducing the deleterious effects of the AGE–RAGE interactions is being actively investigated and showing signs of promise in treating diabetic cardiomyopathy and associated heart failure. This review shall discuss the formation of AGEs in diabetic heart tissue, potential targets of glycation in the myocardium, and underlying mechanisms that lead to diabetic cardiomyopathy and heart failure along with the use of AGE inhibitors and breakers in mitigating myocardial injury.
Literatur
1.
Turner R, Holman R, Cull C, Stratton I, Matthews D, Frighi V, Manley S, Neil A, Mcelroy K, Wright D (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853
2.
Bell DSH (2003) Heart failure the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26(8):2433–2441PubMedCrossRef
3.
Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68(1):85–89PubMedCrossRef
4.
Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34(1):29–34PubMedCrossRef
5.
Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, Vasan RS (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107(3):448–454PubMedCrossRef
6.
7.
Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, Catalano MG, Danni O, Boccuzzi G (2008) Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 149(1):380–388. doi:10.​1210/​en.​2007-0877 PubMedCrossRef
8.
Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS (1983) Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 244(6):E528–E535PubMed
9.
Giacomelli F, Wiener J (1979) Primary myocardial disease in the diabetic mouse. An ultrastructural study. Lab Invest 40(4):460–473PubMed
10.
Regan TJ, Wu CF, Yeh CK, Oldewurtel HA, Haider B (1981) Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res 49(6):1268–1277PubMedCrossRef
11.
12.
Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB (2001) The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37(7):1943–1949PubMedCrossRef
13.
Astorri E, Fiorina P, Contini GA, Albertini D, Magnati G, Astorri A, Lanfredini M (1997) Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol 20(6):536–540PubMedCrossRef
14.
Miyata T, Sugiyama S, Saito A, Kurokawa K (2001) Reactive carbonyl compounds related uremic toxicity (“carbonyl stress”). Kidney Int 59:S25–S31CrossRef
15.
Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48(1):1–9PubMedCrossRef
16.
Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10(4):822–832PubMed
17.
Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ (1994) Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 269(51):32299–32305PubMed
18.
Frye EB, Degenhardt TP, Thorpe SR, Baynes JW (1998) Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 273(30):18714–18719PubMedCrossRef
19.
Ahmed M, Thorpe S, Baynes J (1986) Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261(11):4889–4894PubMed
20.
Schmidt AM, Yan SD, Wautier JL, Stern D (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84(5):489–497PubMedCrossRef
21.
Brownlee M, Vlassara H, Cerami A (1985) Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34(9):938–941PubMedCrossRef
22.
Knecht KJ, Feather MS, Baynes JW (1992) Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: evidence for intermediate stages of the Maillard reaction in vivo. Arch Biochem Biophys 294(1):130–137PubMedCrossRef
23.
Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48(4):870–880PubMedCentralPubMedCrossRef
24.
Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans ROB, Smit AJ (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30(1):107–112PubMedCrossRef
25.
26.
Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Investig 99(3):457–468. doi:10.​1172/​JCI119180 PubMedCrossRef
27.
Schalkwijk CG, Baidoshvili A, Stehouwer CDA, van Hinsbergh VWM, Niessen HWM (2004) Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochimica Biophysica Acta Mol Cell Biol Lipids 1636(2):82–89CrossRef
28.
Hartog JW, de Vries AP, Bakker SJ, Graaff R, van Son WJ, van der Heide JJ, Gans RO, Wolffenbuttel BH, de Jong PE, Smit AJ (2006) Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 21 (8):2263–2269. doi:10.​1093/​ndt/​gfl132
29.
Hartog JWL, Vries APJ, Lutgers HL, Meerwaldt R, Huisman RM, Son WJ, Jong PE, Smit AJ (2005) Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 1043(1):299–307
30.
Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14(3):728–731PubMedCrossRef
31.
Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci 94(25):13915–13920PubMedCrossRef
32.
33.
Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, Regan TJ (1999) Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 48(7):1443–1447PubMedCrossRef
34.
Kumari K, Sahib MK (1993) Susceptibility of different rat tissues to non-enzymatic protein glycosylation in experimental diabetes. Indian J Exp Biol 31(2):194–195PubMed
35.
Berg TJ, Dahl-Jorgensen K, Torjesen PA, Hanssen KF (1997) Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 20(6):1006–1008PubMedCrossRef
36.
Nozynski J, Zakliczynski M, Konecka-Mrowka D, Nikiel B, Mlynarczyk-Liszka J, Zembala-Nozynska E, Lange D, Maruszewski M, Zembala M (2009) Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2. Transpl Proc 41(1):99–104. doi:10.​1016/​j.​transproceed.​2008.​09.​065 CrossRef
37.
Nożyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M (2012) Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Trans Q Polish Trans Soc 17(2):53–61
38.
Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251(2):87–101PubMedCrossRef
39.
40.
41.
Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85(1):87–91PubMedCrossRef
42.
Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF (1999) Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22(7):1186–1190PubMedCrossRef
43.
Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radical Biol Med 28(12):1708–1716CrossRef
44.
Hricik DE, Wu YC, Schulak A, Friedlander MA (1996) Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transpl 10(6 Pt 1):568–573
45.
Dorrian CA, Cathcart S, Clausen J, Shapiro D, Dominiczak MH (1998) Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Mol Biol 44(7):1069–1079PubMed
46.
Garvey WT, Hardin D, Juhaszova M, Dominguez JH (1993) Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy. Am J Physiol 264(3 Pt 2):H837–H844PubMed
47.
Rodrigues B, Cam MC, Kong J, Goyal RK, McNeill JH (1997) Strain differences in susceptibility to streptozotocin-induced diabetes: effects on hypertriglyceridemia and cardiomyopathy. Cardiovasc Res 34(1):199–205PubMedCrossRef
48.
Hall JL, Henderson J, Hernandez LA, Kellerman LA, Stanley WC (1996) Hyperglycemia results in an increase in myocardial interstitial glucose and glucose uptake during ischemia. Metabolism 45(5):542–549PubMedCrossRef
49.
Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, Fukumoto H, Seino S (1990) Molecular biology of mammalian glucose transporters. Diabetes Care 13(3):198–208PubMedCrossRef
50.
51.
Doria-Medina CL, Lund DD, Pasley A, Sandra A, Sivitz WI (1993) Immunolocalization of GLUT-1 glucose transporter in rat skeletal muscle and in normal and hypoxic cardiac tissue. Am J Physiol 265(3 Pt 1):E454–E464PubMed
52.
Kraegen EW, Sowden JA, Halstead MB, Clark PW, Rodnick KJ, Chisholm DJ, James DE (1993) Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. Biochem J 295(Pt 1):287–293
53.
Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC 3rd (1994) Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 89(2):793–798PubMedCrossRef
54.
Slot JW, Geuze HJ, Gigengack S, James DE, Lienhard GE (1991) Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci USA 88(17):7815–7819PubMedCrossRef
55.
Flier JS, Mueckler MM, Usher P, Lodish HF (1987) Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235(4795):1492–1495PubMedCrossRef
56.
Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJA, Frazier O (2002) Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 97(4):203–209PubMedCrossRef
57.
Santalucia T, Boheler KR, Brand NJ, Sahye U, Fandos C, Vinals F, Ferre J, Testar X, Palacin M, Zorzano A (1999) Factors involved in GLUT-1 glucose transporter gene transcription in cardiac muscle. J Biol Chem 274(25):17626–17634PubMedCrossRef
58.
Taegtmeyer H (1994) Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 19(2):59–113PubMedCrossRef
59.
Russell RR III, Mrus JM, Mommessin JI, Taegtmeyer H (1992) Compartmentation of hexokinase in rat heart. A critical factor for tracer kinetic analysis of myocardial glucose metabolism. J Clin Investig 90(5):1972–1977. doi:10.​1172/​JCI116076
60.
Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, Li J, Ren J (2009) Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13(8B):1751–1764. doi:10.​1111/​j.​1582-4934.​2008.​00547.​x
61.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7):889–901PubMedCrossRef
62.
Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Investig 94(1):110–117. doi:10.​1172/​JCI117296 PubMedCrossRef
63.
Szwergold BS, Kappler F, Brown TR (1990) Identification of fructose 3-phosphate in the lens of diabetic rats. Science 247(4941):451–454PubMedCrossRef
64.
Baynes JW (2002) The Maillard hypothesis on aging: time to focus on DNA. Ann N Y Acad Sci 959(1):360–367PubMedCrossRef
65.
Thornalley P, Westwood M, Lo T, McLellan A (1995) Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 112:24–31PubMed
66.
Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109–116
67.
Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Investig 101(5):1142–1147. doi:10.​1172/​JCI119885 PubMedCrossRef
68.
Thornalley PJ (2003) Glyoxalase I–structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31(Pt 6):1343–1348. doi:10.​1042/​ PubMedCrossRef
69.
70.
Misra K, Banerjee AB, Ray S, Ray M (1996) Reduction of methylglyoxal in Escherichia coli K 12 by an aldehyde reductase and alcohol dehydrogenase. Mol Cell Biochem 156(2):117–124PubMedCrossRef
71.
Baba SP, Barski OA, Ahmed Y, O’Toole TE, Conklin DJ, Bhatnagar A, Srivastava S (2009) Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 58(11):2486–2497. doi:10.​2337/​db09-0375 PubMedCrossRef
72.
Penpargkul S, Fein F, Sonnenblick EH, Scheuer J (1981) Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 13(3):303–309PubMedCrossRef
73.
Bouchard RA, Bose D (1991) Influence of experimental diabetes on sarcoplasmic reticulum function in rat ventricular muscle. Am J Physiol 260(2 Pt 2):H341–H354PubMed
74.
Lagadic-Gossmann D, Buckler KJ, Le Prigent K, Feuvray D (1996) Altered Ca2+ handling in ventricular myocytes isolated from diabetic rats. Am J Physiol 270(5 Pt 2):H1529–H1537PubMed
75.
Hansford RG (1994) Physiological role of mitochondrial Ca 2+ transport. J Bioenerg Biomembr 26(5):495–508PubMedCrossRef
76.
Davidoff AJ, Mason MM, Davidson MB, Carmody MW, Hintz KK, Wold LE, Podolin DA, Ren J (2004) Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab 286(5):E718–E724PubMedCrossRef
77.
Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH (2002) Overexpression of the sarcoplasmic reticulum Ca2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51(4):1166–1171PubMedCrossRef
78.
Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, Abel ED (2002) Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Investig 109(5):629–639. doi:10.​1172/​JCI13946 PubMed
79.
Aasum E, Hafstad AD, Severson DL, Larsen TS (2003) Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52(2):434–441PubMedCrossRef
80.
Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR Jr (2004) Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 53(2):463–473PubMedCrossRef
81.
Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M, Dincer UD, Besch HR Jr (2003) Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52(7):1825–1836PubMedCrossRef
82.
83.
Guner S, Arioglu E, Tay A, Tasdelen A, Aslamaci S, Bidasee KR, Dincer UD (2002) Diabetes alter mRNA levels of calcium-release channels in human atrial appendage. J Mol Cell Cardiol 34(6):A84CrossRef
84.
Razeghi P, Young ME, Cockrill TC, Frazier OH, Taegtmeyer H (2002) Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation 106(4):407–411PubMedCrossRef
85.
Yu Z, Tibbits GF, McNeill JH (1994) Cellular functions of diabetic cardiomyocytes: contractility, rapid-cooling contracture, and ryanodine binding. Am J Physiol 266(5 Pt 2):H2082–H2089PubMed
86.
Teshima Y, Takahashi N, Saikawa T, Hara M, Yasunaga S, Hidaka S, Sakata T (2000) Diminished expression of sarcoplasmic reticulum Ca <sup> 2+ </sup>-ATPase and Ryanodine Sensitive Ca <sup> 2+ </sup> Channel mRNA in Streptozotocin-induced Diabetic Rat Heart. J Mol Cell Cardiol 32(4):655–664PubMedCrossRef
87.
Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS (2001) Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50(9):2133–2138PubMedCrossRef
88.
Zhong Y, Ahmed S, Grupp IL, Matlib MA (2001) Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 281(3):H1137–H1147PubMed
89.
Bidasee KR, Dincer UD, Besch HR Jr (2001) Ryanodine receptor dysfunction in hearts of streptozotocin-induced diabetic rats. Mol Pharmacol 60(6):1356–1364PubMed
90.
Bidasee KR, Nallani K, Henry B, Dincer UD, Besch HR Jr (2003) Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. Mol Cell Biochem 249(1–2):113–123PubMedCrossRef
91.
Ren J, Gintant GA, Miller RE, Davidoff AJ (1997) High extracellular glucose impairs cardiac EC coupling in a glycosylation-dependent manner. Am J Physiol Heart Circ Physiol 273(6):H2876–H2883
92.
Parker GJ, Lund KC, Taylor RP, McClain DA (2003) Insulin resistance of glycogen synthase mediated byo-linked N-acetylglucosamine. J Biol Chem 278(12):10022–10027PubMedCrossRef
93.
Marshall S, Garvey W, Traxinger R (1991) New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J 5(15):3031–3036PubMed
94.
Vosseller K, Wells L, Lane MD, Hart GW (2002) Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 99(8):5313–5318. doi:10.​1073/​pnas.​072072399 PubMedCrossRef
95.
Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillmann WH (2003) Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278(45):44230–44237PubMedCrossRef
96.
Baker DL, Dave V, Reed T, Periasamy M (1996) Multiple Sp1 binding sites in the Cardiac/Slow Twitch Muscle Sarcoplamsic Reticulum Ca-ATPase gene promoter are required for expression in Sol8 muscle cells. J Biol Chem 271(10):5921–5928PubMedCrossRef
97.
Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE (2001) O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA 98(12):6611–6616. doi:10.​1073/​pnas.​111099998 PubMedCrossRef
98.
Smit AJ, Lutgers HL (2004) The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11(20):2767–2784PubMedCrossRef
99.
100.
Tanaka S, Avigad G, Brodsky B, Eikenberry EF (1988) Glycation induces expansion of the molecular packing of collagen. J Mol Biol 203(2):495–505PubMedCrossRef
101.
Haitoglou C, Tsilibary E, Brownlee M, Charonis A (1992) Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 267(18):12404–12407PubMed
102.
Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104(13):1464–1470PubMedCrossRef
103.
Paul RG, Bailey AJ (1999) The effect of advanced glycation end-product formation upon cell-matrix interactions. Int J Biochem Cell Biol 31(6):653–660PubMedCrossRef
104.
Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91(20):9441–9445PubMedCrossRef
105.
Posch K, Simecek S, Wascher TC, Jurgens G, Baumgartner-Parzer S, Kostner GM, Graier WF (1999) Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated l-arginine uptake in endothelial cells. Diabetes 48(6):1331–1337PubMedCrossRef
106.
Gempel KE, Gerbitz KD, Olgemoller B, Schleicher ED (1993) In-vitro carboxymethylation of low density lipoprotein alters its metabolism via the high-affinity receptor. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 25(5):250–252. doi:10.​1055/​s-2007-1002089
107.
Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A et al (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143(6):1699–1712PubMed
108.
Striker LJ, Striker GE (1996) Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 11(suppl 5):62–65
109.
Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M (1995) PDGF and TGF-bold beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48:111–117PubMedCrossRef
110.
Bucala R, Tracey KJ, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Investig 87(2):432–438. doi:10.​1172/​JCI115014 PubMedCrossRef
111.
Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267(21):14987–14997PubMed
112.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267(21):14998–15004PubMed
113.
Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, Ramasamy R (2008) RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57(7):1941–1951. doi:10.​2337/​db07-0326 PubMedCrossRef
114.
Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, Inoko H, Ikemura T (1994) Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23(2):408–419PubMedCrossRef
115.
Li J, Schmidt AM (1997) Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272(26):16498–16506PubMedCrossRef
116.
117.
Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D (1999) N ε-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274(44):31740–31749PubMedCrossRef
118.
Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Investig 108(7):949–956PubMed
119.
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258(5082):651–653PubMedCrossRef
120.
Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Investig 91(6):2463–2469. doi:10.​1172/​JCI116481 PubMedCrossRef
121.
122.
Stern DM, Yan SD, Yan SF, Schmidt AM (2002) Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1(1):1–15PubMedCrossRef
123.
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83(11):876–886. doi:10.​1007/​s00109-005-0688-7 CrossRef
124.
Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4(9):1025–1031. doi:10.​1038/​2012 PubMedCrossRef
125.
Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Investig 111(7):959–972. doi:10.​1172/​JCI17115 PubMed
126.
Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159(2):513–525. doi:10.​1016/​S0002-9440(10)61723-3 PubMedCrossRef
127.
Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati VD, Schmidt AM (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162(4):1123–1137. doi:10.​1016/​S0002-9440(10)63909-0 PubMedCrossRef
128.
Nielsen JM, Kristiansen SB, Norregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Botker HE (2009) Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 11(7):638–647. doi:10.​1093/​eurjhf/​hfp070 PubMedCrossRef
129.
Bu DX, Rai V, Shen X, Rosario R, Lu Y, D’Agati V, Yan SF, Friedman RA, Nuglozeh E, Schmidt AM (2010) Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res 106(6):1040–1051. doi:10.​1161/​CIRCRESAHA.​109.​201103 PubMedCentralPubMedCrossRef
130.
Stitt AW, Bucala R, Vlassara H (2006) Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann N Y Acad Sci 811(1):115–129
131.
Bucciarelli L, Wendt T, Rong L, Lalla E, Hofmann M, Goova M, Taguchi A, Yan S, Yan S, Stern D (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59(7):1117–1128PubMedCrossRef
132.
Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S (1043) Chen Y (2006) Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1:553–561
133.
Thornalley PJ (1990) The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269(1):1–11PubMed
134.
Thornalley PJ (1998) Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111–112:137–151PubMedCrossRef
135.
Szwergold BS, Howell S, Beisswenger PJ (2001) Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 50(9):2139–2147PubMedCrossRef
136.
Boel E, Selmer J, Flodgaard HJ, Jensen T (1995) Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise? J Diabetes Complicat 9(2):104–129PubMedCrossRef
137.
Suzuki K, Koh YH, Mizuno H, Hamaoka R, Taniguchi N (1998) Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone. J Biochem 123(2):353–357PubMedCrossRef
138.
Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE (2001) Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 130(1–3):549PubMedCrossRef
139.
Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P (1996) An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382(6588):275–278. doi:10.​1038/​382275a0 PubMedCrossRef
140.
Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95(8):4630–4634PubMedCrossRef
141.
Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P, Levy BI (1993) Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Investig 92(3):1407–1411. doi:10.​1172/​JCI116716 PubMedCrossRef
142.
Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, Williams C, Torres RL, Wagle D, Ulrich P (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci 97(6):2809–2813PubMedCrossRef
143.
Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasan S, Wagle DR, Ulrich P, Brines M (2001) A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci 98(3):1171–1175PubMedCrossRef
144.
Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A (2003) Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 285(6):H2587–H2591. doi:10.​1152/​ajpheart.​00516.​2003 PubMed
145.
146.
147.
Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53(7):1813–1823PubMedCrossRef
148.
Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta RC, Chauthaiwale V, Dutt C (2009) TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 54(1):72–81. doi:10.​1097/​FJC.​0b013e3181ac3a34​ PubMedCrossRef
149.
Pathak P, Gupta R, Chaudhari A, Shiwalkar A, Dubey A, Mandhare AB, Gupta RC, Joshi D, Chauthaiwale V (2008) TRC4149 a novel advanced glycation end product breaker improves hemodynamic status in diabetic spontaneously hypertensive rats. Eur J Med Res 13(8):388–398PubMed
150.
Cheng G, Wang LL, Long L, Liu HY, Cui H, Qu WS, Li S (2007) Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats. Br J Pharmacol 152(8):1196–1206. doi:10.​1038/​sj.​bjp.​0707533 PubMedCrossRef
151.
Kranstuber AL, del Rio C, Biesiadecki BJ, Hamlin RL, Ottobre J, Gyorke S, Lacombe VA (2012) Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Frontiers Physiol 3:292. doi:10.​3389/​fphys.​2012.​00292. Epub 2012 July 19
152.
Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11(3):191–195PubMedCrossRef
153.
Kalousova M, Skrha J, Zima T (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res Academia Scientiarum Bohemoslovaca 51(6):597–604
154.
Kostolanska J, Jakus V, Barak L (2009) Monitoring of early and advanced glycation in relation to the occurrence of microvascular complications in children and adolescents with type 1 diabetes mellitus. Physiol Res Academia Scientiarum Bohemoslovaca 58(4):553–561
155.
Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30(3):670–676. doi:10.​2337/​dc06-1508 PubMedCrossRef
156.
Kanauchi M, Nishioka H, Dohi K (2001) Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron 89(2):228–230. doi:46073 PubMedCrossRef
157.
Perkins BA, Rabbani N, Weston A, Ficociello LH, Adaikalakoteswari A, Niewczas M, Warram J, Krolewski AS, Thornalley P (2012) Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS ONE 7(4):e35655. doi:10.​1371/​journal.​pone.​0035655 PubMedCentralPubMedCrossRef
158.
Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22(9):1543–1548PubMedCrossRef
159.
Metadaten
Titel
Advanced glycation end products: role in pathology of diabetic cardiomyopathy
verfasst von
Vijaya Lakshmi Bodiga
Sasidhar Reddy Eda
Sreedhar Bodiga
Publikationsdatum
01.01.2014
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 1/2014
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-013-9374-y

Weitere Artikel der Ausgabe 1/2014

Heart Failure Reviews 1/2014 Zur Ausgabe

OriginalPaper

Mechanisms of subcellular remodeling in heart failure due to diabetes

OriginalPaper

Chronic effects of mild hyperglycaemia on left ventricle transcriptional profile and structural remodelling in the spontaneously type 2 diabetic Goto-Kakizaki rat

OriginalPaper

Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy

OriginalPaper

Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants

OriginalPaper

Metabolic dysfunction in diabetic cardiomyopathy

OriginalPaper

Alternative therapies for diabetes and its cardiac complications: role of vanadium

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

24.04.2024 | Adipositas | Nachrichten

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 | ACC 2024 | Nachrichten

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen